Stay updated on Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.

Latest updates to the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no visible changes to the study details content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedThe government funding and NIH operating status notice was removed from the page; core trial details such as study plan, locations, and eligibility remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page now shows an expanded list of study locations and updated contact details. The core study design, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.2%

- Check63 days agoChange Detected- Updated notice about government funding lapse and current operating status with links to official sources. - Version bumped from v3.1.0 to v3.2.0.SummaryDifference3%

- Check70 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.1%

- Check85 days agoChange DetectedVersion updated to v3.0.2, replacing v3.0.1; the 'Back to Top' link was removed.SummaryDifference0.2%

Stay in the know with updates to Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.